TPX-100: OrthoTrophix Published a New Research Article Demonstrating Disease Modification in Knee Osteoarthritis

FOSTER CITY, Calif.: FOSTER CITY, Calif., Sept. 21, 2021 /PRNewswire/ -- OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company and its collaborators have published a new research article presenting clinical data demonstrating disease modification in knee osteoarthritis (OA) patients treated with TPX-100, the Company's leading candidate...

Click to view original post